查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球細菌性結膜炎市場：增長、未來展望、競爭分析 (2022-2030)
市場調查報告書
商品編碼
1166610

全球細菌性結膜炎市場：增長、未來展望、競爭分析 (2022-2030)

Bacterial Conjunctivitis Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 119 Pages | 商品交期: 最快1-2個工作天內

價格

細菌性結膜炎、水和空氣污染以及個人不衛生條件的日益流行是導致細菌性結膜炎治療藥物深入市場滲透的因素之一。 具有有效藥物濃度（例如 ISV-405（阿奇黴素 2.0%））的藥物開發技術進步由於劑量要求最低而導致起效更快，因此與藥物相關的不良事件更少 細菌性結膜炎可檢測的參數非常有限，腺病毒和細菌性結膜炎之間症狀的模糊重疊使得缺乏有效的給藥成為主要限制。

按地區分析 2021 年細菌性結膜炎的市場規模時，北美被確認是最大的。 據報導，2016 年該地區約有 300 萬患者患有細菌性結膜炎。 北美的主導地位主要歸因於細菌性結膜炎患病率上升、發達研究和醫療機構的存在以及負擔得起的報銷方案等因素。 另一方面，亞太地區被認為是預測期內（2022-2030 年）增長最快的區域部分。 預計將推動市場增長的因素包括可支配收入的增加和細菌性結膜炎產品的支持性監管環境。

本報告分析了全球細菌性結膜炎治療市場，概述了疾病、市場的宏觀和微觀環境因素、主要市場驅動因素和製約因素以及整體市場規模趨勢。我們將為您提供全面的信息例如前景（2020-2030）、按藥物類別和地區劃分的詳細趨勢、主要市場驅動因素和製約因素、主要參與者的概況和增長戰略。

內容

第一章介紹

第 2 章執行摘要

第 3 章細菌性結膜炎市場：競爭分析

  • 細菌性結膜炎市場：主要供應商的市場定位
  • 供應商在細菌性結膜炎市場採用的策略
  • 主要行業戰略
  • 層次分析 (2021/2030)

第 4 章細菌性結膜炎市場：宏觀分析和市場動態

  • 介紹
  • 全球細菌性結膜炎市場規模（單位：百萬美元，2020-2030 年）
  • 市場動態
    • 市場驅動因素
    • 市場製約因素
    • 主要問題
    • 主要機會
  • 促進因素和抑制因素的影響分析
  • 蹺蹺板分析
  • 波特的五力模型
  • PESTEL 分析
  • 七度分析
  • 業務關鍵問題分析：5 個根本原因分析和相關解決方案

第 5 章細菌性結膜炎市場：按藥物類別分類（單位：百萬美元，2020-2030 年）

  • 市場概覽
  • 增長和收益分析 (2021/2030)
  • 市場細分
    • 氟奎諾酮
    • 氨基糖甘類
    • 大環內酯
    • 其他（苯酚、醣脂□、環狀多□）

第六章區域分析

  • 市場概覽
  • 宏觀因素和市場影響：儀表板 (2021)
  • 按地區劃分的波特五力模型：儀表板 (2021)
  • PESTEL 因素的區域影響：儀表板 (2021)

第 7 章北美細菌性結膜炎市場（單位：百萬美元，2020-2030）

  • 市場概覽
  • 細菌性結膜炎市場：按藥物類別分類（單位：百萬美元，2020-2030 年）
  • 細菌性結膜炎市場：按地區（單位：百萬美元，2020-2030 年）
    • 北美

第 8 章英國和歐盟國家的細菌性結膜炎市場（單位：百萬美元，2020-2030）

第 9 章亞太細菌性結膜炎市場（單位：百萬美元，2020-2030 年）

第 10 章拉丁美洲細菌性結膜炎市場（單位：百萬美元，2020-2030 年）

第 11 章中東和非洲細菌性結膜炎市場（單位：百萬美元，2020-2030 年）

第12章公司簡介

  • Actavis Plc.
  • Akorn, Inc.
  • Bayer AG
  • F.Hoffman La-Roche Ltd.
  • InSite Vision Incorporated
  • Merck & Co., Inc.
  • Novartis AG
  • Perrigo Company Plc.
  • Pfizer, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Other Notable Players
Product Code: 137324-08-22

The drivers responsible for the deep market penetration of drugs utilized for treatment of bacterial conjunctivitis are the rising prevalence of bacterial conjunctivitis, water and air pollution and lack of personal hygiene. Technological advancement in the drug development with effective drug concentration such as ISV-405 (Azithromycin 2.0%) which has resulted into immediate relief as the dose required is minimum and hence less drug related adverse events. A strong limitation of bacterial conjunctivitis is the number of parameters that can be detected are very limited, and the overlapping of symptoms of adenoviral and bacterial conjunctivitis is ambiguous resulting into ineffective dosage regimen.

For the purpose of this study, the various products studied includes fluoroquinolones, aminoglycosides, macrolides and others. The fluoroquinolones are classified as (Ciprofloxacin, Ofloxacin, Levofloxacin, Moxifloxacin, Gatifloxacin, and Besifloxacin) Aminoglycosides are further classified as (Tobramycin, Gentamycin). Macrolides are categorized as (Erythromycin and Azithromycin). Others consists of (Phenicols, Glycolipopeptides and Cyclic Polypeptides).

The geographic segmentation of the global bacterial conjunctivitis market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global bacterial conjunctivitis market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global bacterial conjunctivitis market. The major players in bacterial conjunctivitis market are Actavis Plc., Akorn, Inc., Bayer AG, F. Hoffman La-Roche Ltd., InSite Vision Incorporated, Merck & Co. Inc., Novartis AG, Perrigo Company Plc., Pfizer, Inc., Santen Pharmaceutical Co. Ltd.

The bacterial conjunctivitis market is driven by factors such as pharmaceutical R&D focusing on treatment of bacterial conjunctivitis, rising public awareness and alliances between pharmaceutical giants and research institutes. In addition, rising prevalence of bacterial conjunctivitis and increasing air and water pollution affecting the eye conjunctiva. In 2016, fluoroquinolones segment held the largest market share chiefly due to factors such as the broad spectrum antimicrobial activity offered by fluoroquinolones against the Gram-positive, Gram-negative and anaerobic organisms. Technological advancement in the drug formulation has rendered current generation fluoroquinolones such as gatifloxacin, moxifloxacin and besifloxacin as first line of treatment. The limitations of this segment throughout the forecast period is the forthcoming patent expiration of blockbuster branded drugs of the fluoroquinolones drug class. Aminoglycosides and macrolides together will be the fastest growing segment throughout the forecast period 2022-2030. Factors contributing to the growth of this segment are increasing incidences of antibiotics related drug resistance in bacterial conjunctivitis patients and technological advancement with effective clinical trials conducted to analyze safety and efficacy related to the drug formulation of antibiotics at different concentration resulting in immediate relief due to faster onset of action. The major players in bacterial conjunctivitis market are Actavis Plc., Akorn, Inc., Bayer AG, F.Hoffman La-Roche Ltd., InSite Vision Incorporated, Merck & Co. Inc., Novartis AG, Perrigo Company Plc., Pfizer, Inc., Santen Pharmaceutical Co., Ltd.

North America was observed to be the largest market for bacterial conjunctivitis in the base year 2021. According to the National Eye Institute, in 2016, about 3 million cases are reported suffering with bacterial conjunctivitis. The dominance of North America is mainly attributed to the presence of key drivers such as rising prevalence of bacterial conjunctivitis, existence of developed research and healthcare institutions and affordable reimbursement scenario. The market growth in Europe is mainly attributed to the rising prevalence of air and water pollution, presence of pharmaceutical giants pioneering in the treatment of bacterial conjunctivitis. Asia Pacific was observed as the fastest growing regional segment throughout the forecast period 2022-2030. Factors that are anticipated to propel the market growth are increasing disposable income and supportive regulatory environment for bacterial conjunctivitis products. Moreover, factors such as developing health infrastructure, business expansion by pharmaceutical giants in the untapped markets with unmet medical needs are going to fuel the rapid growth of bacterial conjunctivitis market in Latin America, and Middle East and Africa in the near future.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Bacterial Conjunctivitis market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Bacterial Conjunctivitis market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • Fluoroquinolones
    • Ciprofloxacin
    • Ofloxacin
    • Levofloxacin
    • Moxifloxacin
    • Gatifloxacin
    • Besifloxacin
  • Aminoglycosides
    • Tobramycin
    • Gentamycin
  • Macrolides
    • Erythromycin
    • Azithromycin
  • Others (Phenicols, Glycolipopeptides, Cyclic Polypeptides)

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Bacterial Conjunctivitis market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Bacterial Conjunctivitis market?
  • Which is the largest regional market for Bacterial Conjunctivitis market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Bacterial Conjunctivitis market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Bacterial Conjunctivitis market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Bacterial Conjunctivitis Market
  • 2.2. Global Bacterial Conjunctivitis Market, By Drug Class, 2021 (US$ Million)
  • 2.3. Global Bacterial Conjunctivitis Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021
  • 2.5. Key Buying Criteria
  • 2.6. Key Case Reports
  • 2.7. Scenario Analysis
    • 2.7.1. Optimistic estimates and analysis
    • 2.7.2. Realistic estimates and analysis
    • 2.7.3. Pessimistic estimates and analysis
  • 2.8. Market Profiling
  • 2.9. Sales and Marketing Plan
  • 2.10. Top Market Conclusions
  • 2.11. Strategic Recommendations

3. Bacterial Conjunctivitis Market: Competitive Analysis

  • 3.1. Market Positioning of Key Bacterial Conjunctivitis Market Vendors
  • 3.2. Strategies Adopted by Bacterial Conjunctivitis Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Bacterial Conjunctivitis Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Bacterial Conjunctivitis Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape
  • 4.8. Heptalysis Analysis
  • 4.9. Critical Investigation of Business Problems Through Five Whys Root Cause Analysis & Relevant Solutions

5. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Fluoroquinolones
      • 5.3.1.1. Ciprofloxacin
      • 5.3.1.2. Ofloxacin
      • 5.3.1.3. Levofloxacin
      • 5.3.1.4. Moxifloxacin
      • 5.3.1.5. Gatifloxacin
      • 5.3.1.6. Besifloxacin
    • 5.3.2. Aminoglycosides
      • 5.3.2.1. Tobramycin
      • 5.3.2.2. Gentamycin
    • 5.3.3. Macrolides
      • 5.3.3.1. Erythromycin
      • 5.3.3.2. Azithromycin
    • 5.3.4. Others (Phenicols, Glycolipopeptides, Cyclic Polypeptides)

6. Geographic Analysis

  • 6.1. Market Overview
  • 6.2.Macro Factors versus Market Impact: Dashboard, 2021
  • 6.3. Porters Five Force Model Across Geography: Dashboard, 2021
  • 6.4. Impact of PESTEL factors Across Geography: Dashboard, 2021

7. North America Bacterial Conjunctivitis Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
  • 7.3.Bacterial Conjunctivitis Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.North America
      • 7.3.1.1. U.S.
        • 7.3.1.1.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.2. Canada
        • 7.3.1.2.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.3. Rest of North America
        • 7.3.1.3.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)

8. UK and European Union Bacterial Conjunctivitis Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
  • 8.3.Bacterial Conjunctivitis Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.UK and European Union
      • 8.3.1.1. UK
        • 8.3.1.1.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.2. Germany
        • 8.3.1.2.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.3. Spain
        • 8.3.1.3.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.4. Italy
        • 8.3.1.4.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.5. France
        • 8.3.1.5.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Europe
        • 8.3.1.6.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)

9. Asia Pacific Bacterial Conjunctivitis Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
  • 9.3.Bacterial Conjunctivitis Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Asia Pacific
      • 9.3.1.1. China
        • 9.3.1.1.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.2. Japan
        • 9.3.1.2.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.3. India
        • 9.3.1.3.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.4. Australia
        • 9.3.1.4.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.5. South Korea
        • 9.3.1.5.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.6. Rest of Asia Pacific
        • 9.3.1.6.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)

10. Latin America Bacterial Conjunctivitis Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
  • 10.3.Bacterial Conjunctivitis Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Latin America
      • 10.3.1.1. Brazil
        • 10.3.1.1.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 10.3.1.2. Mexico
        • 10.3.1.2.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Latin America
        • 10.3.1.3.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)

11. Middle East and Africa Bacterial Conjunctivitis Market, 2020-2030, USD (Million)

  • 11.1. Market Overview
  • 11.2. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
  • 11.3.Bacterial Conjunctivitis Market: By Region, 2020-2030, USD (Million)
    • 11.3.1.Middle East and Africa
      • 11.3.1.1. GCC
        • 11.3.1.1.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 11.3.1.2. Africa
        • 11.3.1.2.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)
      • 11.3.1.3. Rest of Middle East and Africa
        • 11.3.1.3.1. Bacterial Conjunctivitis Market: By Drug Class, 2020-2030, USD (Million)

12. Company Profile

  • 12.1. Actavis Plc.
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Akorn, Inc.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Bayer AG
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. F.Hoffman La-Roche Ltd.
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. InSite Vision Incorporated
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Merck & Co., Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Novartis AG
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Perrigo Company Plc.
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Pfizer, Inc.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Santen Pharmaceutical Co., Ltd.
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Other Notable Players
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 2 Global Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 3 Global Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 4 Global Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 5 North America Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 6 North America Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 7 North America Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 8 North America Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 9 U.S. Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 10 U.S. Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 11 U.S. Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 12 U.S. Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 13 Canada Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 14 Canada Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 15 Canada Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 16 Canada Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 17 Rest of North America Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 18 Rest of North America Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 19 Rest of North America Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 20 Rest of North America Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 21 UK and European Union Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 22 UK and European Union Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 23 UK and European Union Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 24 UK and European Union Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 25 UK Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 26 UK Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 27 UK Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 28 UK Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 29 Germany Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 30 Germany Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 31 Germany Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 32 Germany Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 33 Spain Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 34 Spain Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 35 Spain Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 36 Spain Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 37 Italy Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 38 Italy Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 39 Italy Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 40 Italy Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 41 France Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 42 France Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 43 France Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 44 France Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 45 Rest of Europe Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 46 Rest of Europe Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 47 Rest of Europe Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 48 Rest of Europe Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 49 Asia Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 50 Asia Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 51 Asia Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 52 Asia Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 53 China Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 54 China Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 55 China Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 56 China Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 57 Japan Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 58 Japan Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 59 Japan Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 60 Japan Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 61 India Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 62 India Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 63 India Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 64 India Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 65 Australia Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 66 Australia Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 67 Australia Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 68 Australia Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 69 South Korea Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 70 South Korea Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 71 South Korea Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 72 South Korea Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 73 Latin America Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 74 Latin America Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 75 Latin America Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 76 Latin America Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 77 Brazil Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 78 Brazil Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 79 Brazil Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 80 Brazil Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 81 Mexico Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 82 Mexico Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 83 Mexico Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 84 Mexico Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 85 Rest of Latin America Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 86 Rest of Latin America Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 87 Rest of Latin America Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 88 Rest of Latin America Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 89 Middle East and Africa Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 90 Middle East and Africa Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 91 Middle East and Africa Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 92 Middle East and Africa Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 93 GCC Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 94 GCC Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 95 GCC Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 96 GCC Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 97 Africa Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 98 Africa Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 99 Africa Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 100 Africa Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)
  • TABLE 101 Rest of Middle East and Africa Bacterial Conjunctivitis Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 102 Rest of Middle East and Africa Bacterial Conjunctivitis Market By Fluoroquinolones, 2020-2030, USD (Million)
  • TABLE 103 Rest of Middle East and Africa Bacterial Conjunctivitis Market By Aminoglycosides, 2020-2030, USD (Million)
  • TABLE 104 Rest of Middle East and Africa Bacterial Conjunctivitis Market By Macrolides, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Bacterial Conjunctivitis Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Bacterial Conjunctivitis Market: Quality Assurance
  • FIG. 5 Global Bacterial Conjunctivitis Market, By Drug Class, 2021
  • FIG. 6 Global Bacterial Conjunctivitis Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Bacterial Conjunctivitis Market, 2021
  • FIG. 8 Market Positioning of Key Bacterial Conjunctivitis Market Players, 2021
  • FIG. 9 Global Bacterial Conjunctivitis Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Porters Five Force Model - Current, Midterm and Long Term Perspective
  • FIG. 11 See Saw Analysis
  • FIG. 12 PETEL Analysis
  • FIG. 13 Key Buying Criteria: Current and Long-Term Perspective
  • FIG. 14 Global Bacterial Conjunctivitis Market, Scenario Analysis, 2020 to 2030 (US$ Million)
  • FIG. 15 Heptalysis Analysis: Global Bacterial Conjunctivitis Market
  • FIG. 16 Five Whys Analysis
  • FIG. 17 Global Bacterial Conjunctivitis Market, By Drug Class, 2021 Vs 2030, %
  • FIG. 18 U.S. Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 19 Canada Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 20 Rest of North America Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 21 UK Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 22 Germany Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 23 Spain Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 24 Italy Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 25 France Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 26 Rest of Europe Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 27 China Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 28 Japan Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 29 India Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 30 Australia Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 31 South Korea Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 32 Rest of Asia Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 33 Brazil Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 34 Mexico Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 35 Rest of Latin America Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 36 GCC Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 37 Africa Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030
  • FIG. 38 Rest of Middle East and Africa Bacterial Conjunctivitis Market (US$ Million), 2020 - 2030